Breast density influences tumor subtypes and tumor aggressiveness

Journal of the National Cancer Institute

Volumn 103, Issue 15, 2011, Pages 1143-1145

  Kerlikowske, Karla ^a,b   Phipps, Amanda I ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TESTOSTERONE;

BODY MASS; BREAST CANCER; BREAST EPITHELIUM; CANCER CLASSIFICATION; CANCER RISK; CELL PROLIFERATION; DENSITY; DISEASE ASSOCIATION; DNA REPLICATION; EDITORIAL; FIBROBLAST; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; MAMMOGRAPHY; MENARCHE; PARITY; POSTMENOPAUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MAMMOGRAPHY; NEOPLASM INVASIVENESS; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79961236830     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr263     Document Type: Editorial

References (41)

1. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1558- 1568. (Pubitemid 39331875)
2. Onitilo A, Engel J, Greenlee R, Mukesh B. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1-2):4-13.
3. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc. 2006;295(21):2492-2502. (Pubitemid 43854964)
4. Kim M, Ro J, Ahn S, Kim H, Kim S, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37(9):1217-1226. (Pubitemid 44286991)
5. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009;113(2):357-370.
6. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40(18):2667-2675. (Pubitemid 39574720)
7. Ma H, Wang Y, Sullivan-Halley J, et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res. 2010;70(2):575-587.
8. Rosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology. 1998;209(2):511-518. (Pubitemid 28503121)
9. Phipps A, Malone K, Porter P, Daling J, Li C. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer. 2008;113(7):1521-1526.
10. Yang X, Chang-Claude J, Goode E, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium Studies. J Natl Cancer Inst. 2011;103(3):250-263.
11. Menashe I, Anderson W, Jatoi I, Rosenberg P. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst. 2009;101(14):993-1000.
12. Hausauer A, Keegan T, Chang E, Clarke C. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype. Breast Cancer Res. 2007;9(6):R90.
13. Farhat GN, Cummings S, Chlebowski RT, et al. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Clin Oncol. 2011;103(7):562-570.
14. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995;87(21):1622-1629.
15. Lee-Han H, Cooke G, Boyd NF. Quantitative evaluation of mammographic densities: a comparison of methods of assessment. Eur J Cancer Prev. 1995;4(4):285-292.
16. Vacek PM, Geller BM. Prospective study of breast cancer risk using routine mammographic breast density measurements. Cancer Epidemiol Biomarkers Prev. 2004;13(5):715-722. (Pubitemid 38737858)
17. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98(17):1204-1214. (Pubitemid 44390991)
18. Guo YP, Martin LJ, Hanna W, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev. 2001;10(3):243-248. (Pubitemid 34288536)
19. Li T, Sun L, Miller N, et al. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(2):343-349. (Pubitemid 40270095)
20. Ziv E, Tice J, Smith-Bindman R, Shepherd J, Cummings S, Kerlikowske K. Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2090-2095. (Pubitemid 40054303)
21. Ma H, Luo J, Press M, Wang Y, Bernstein L, Ursin G. Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(2):479-485.
22. Aiello E, Buist D, White E, Porter P. Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2005;14(3):662-668. (Pubitemid 40489212)
23. Fasching PA, Heusinger K, Loehberg CR, et al. Influence of mammographic breast density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics. Eur J Radiol. 2006;60(3):398-404.
24. Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008;111(3):405-410.
25. Chen JH, Hsu F, Shih H, et al. Does breast density show difference in patients with estrogen receptor-positive and estrogen receptor-negative breast cancer measured on MRI? Ann Oncol. 2009;20(8):1447-1449.
26. Conroy S, Pagano I, Kolonel L, Maskarinec G. Mammographic density and hormone receptor expression in breast cancer: the Multiethnic Cohort Study [published online ahead of print January 17, 2011]. Cancer Epidemiol. 2011.
27. Ding J, Warren R, Girling A, Thompson D, Easton D. Mammographic density, estrogen receptor status and other breast cancer tumor characteristics. Breast J. 2010;16(3):279-289.
28. Ma H, Wang Y, Sullivan-Halley J, et al. Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev. 2009;18(8):2214-2220.
29. Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 2011;103(15):1179-1189.
30. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227-236. (Pubitemid 46143226)
31. Roubidoux M, Bailey J, Wray L, Helvie M. Invasive cancers detected after breast cancer screening yielded a negative result: relationship of mammographic density to tumor prognostic factors. Radiology. 2004;230(1):42-48. (Pubitemid 37549781)
32. Buist D, Porter P, Lehman C, Taplin S, White E. Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst. 2004;96(19):1432-1440. (Pubitemid 39429667)
33. Olumi A, Grossfeld G, Hayward S, Carroll P, Tlsty T, Cunha G. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59(19):5002-5011. (Pubitemid 29472907)
34. Ghosh K, Brandt K, Sellers T, et al. Association of mammographic density with the pathology of subsequent breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17(4):872-879. (Pubitemid 351536418)
35. Porter G, Evans A, Cornford E, et al. Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol. 2007;188(3):676-683.
36. Sala E, Solomon L, Warren R, et al. Size, node status and grade of breast tumours: association with mammographic parenchymal patterns. Eur Radiol. 2000;10(1):157-161. (Pubitemid 30141148)
37. Kerlikowske K, Cook A, Buist DSM, et al. Breast cancer risk by breast density, age, menopause, and postmenopausal hormone therapy use. J Clin Oncol. 2010;28(24):3830-3837.
38. Krieger N, Chen JT, Ware JH, Kaddour A. Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions. Cancer Causes Control. 2008;19(10):1305-1318.
39. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886. (Pubitemid 20026073)
40. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007;99(23):1782-1792. (Pubitemid 351767204)
41. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148(5):337-347. (Pubitemid 351665464)